Synucleinopathies: Clinical Trials

2502 completed, 754 unknown, 662 recruiting, 263 terminated. 2085 Not applicable, 663 Phase 2, 453 Phase 1, 309 Phase 3, 182 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	2085	Completed 989, Unknown 397, Recruiting 332, Not yet recruiting 111, Terminated 93, Active not recruiting 75, Enrolling by invitation 43, Withdrawn 40, Suspended 5
Phase 2	663	Completed 393, Unknown 70, Recruiting 58, Terminated 57, Active not recruiting 30, Withdrawn 27, Not yet recruiting 22, Enrolling by invitation 4, Suspended 2
Phase 1	453	Completed 285, Recruiting 48, Unknown 36, Terminated 28, Not yet recruiting 19, Withdrawn 17, Active not recruiting 16, Enrolling by invitation 3, Suspended 1
Phase 3	309	Completed 222, Terminated 35, Recruiting 18, Unknown 17, Withdrawn 8, Active not recruiting 5, Not yet recruiting 4
Phase 4	182	Completed 110, Unknown 28, Terminated 17, Recruiting 11, Not yet recruiting 6, Enrolling by invitation 4, Withdrawn 4, Active not recruiting 1, Suspended 1
Early Phase 1	63	Completed 25, Recruiting 15, Unknown 7, Not yet recruiting 6, Terminated 5, Withdrawn 3, Active not recruiting 2

Follow Synucleinopathies: new trials by email Literature Review of Synucleinopathies trials Research Report on Synucleinopathies

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD)	Phase 2	Suspended	Ergun Y. Uc	120	2028-07-01	2026-10-09
Double-Blind Clinical Trial of Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease active subthalamic nucleus deep brain stimulation plus optimal drug therapy, inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy - Parkinson Disease	Not applicable	Not yet recruiting	Mallory Hacker	40	2028-01-01	2026-02-20
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease	Phase 2	Withdrawn	Forest Hills Lab		2027-11-01	2026-08-19
Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies	Phase 1 / Phase 2	Not yet recruiting	Qiang Zhang	40	2027-10-01	2026-03-12
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease	Phase 2	Not yet recruiting	Mthera Pharma Co., Ltd.	120	2027-09-01	2026-10-16
Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) rTMS - Parkinson Disease	Not applicable	Not yet recruiting	University of Michigan	20	2027-09-01	2026-10-20
Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics Levodopa (L-dopa) - Parkinson's Disease	Phase 4	Not yet recruiting	Beth Israel Deaconess Medical Center	40	2027-07-01	2026-08-28
Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease Fecal Microbiota Transplant - Parkinson Disease	Phase 1	Not yet recruiting	ProgenaBiome	10	2027-07-01	2026-10-09
Engage-PD: a Physical Activity Coaching Program Via Telehealth for People With Parkinson's Disease. A Single-cohort Study in Spain. Physical Activity Coaching - PARKINSON DISEASE (Disorder)	Not applicable	Not yet recruiting	Hospital Clinic of Barcelona	30	2027-06-01	2026-10-05
Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers	Phase 1 / Phase 2	Not yet recruiting	University of Minnesota	32	2027-04-01	2026-10-01
Expiratory Muscle Training in Parkinson's Disease With Forward Trunk Flexion Expiratory muscle strength training - Parkinson's Disease	Not applicable	Not yet recruiting	General University Hospital, Prague	28	2027-02-01	2026-11-12
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD) AB-1005 - Parkinson Disease	Phase 2	Not yet recruiting	Bayer	8	2027-01-25	2026-07-29
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)		Not yet recruiting	BioSensics	60	2027-01-15	2026-10-13
Magnetic-Resonance Guided Focused Ultrasound Pallidothalamic Tractotomy for Parkinson's Disease MR-guided Focused Ultrasound Pallidothalamic Tractotomy, MR-guided Focused Ultrasound VIM Thalamotomy, Combined MR-guided Focused Ultrasound PTT and VIM Treatment - Parkinson Disease (PD)	Not applicable	Not yet recruiting	Research Center of Neurology, Russia	168	2027-01-15	2026-11-12
Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease Nutricional Education and General Exercise Guidelines, Progressive Resistance Training With Cognitive Dual-Task Training, Progressive Resistance Training With Cognitive Dual-Task and Inestability Training - PARKINSON DISEASE (Disorder), Parkinsonism or Parkinson's Disease Nos	Not applicable	Recruiting	University of Valencia	60	2027-01-11	2026-10-30
Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With PD Effortful swallow - Dysphagia, Parkinson Disease (PD)	Not applicable	Not yet recruiting	University of Alberta	74	2027-01-01	2026-08-19
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant	Phase 3	Not yet recruiting	Ono Pharmaceutical Co., Ltd.	486	2027-01-01	2026-09-17
Probing Gut-Brain Communication in Parkinson's Disease taVNS, Sham taVNS - Parkinson Disease (PD)	Not applicable	Not yet recruiting	Spaulding Rehabilitation Hospital	45	2027-01-01	2026-10-08
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease Talineuren, Placebo - Parkinson Disease	Phase 2	Not yet recruiting	InnoMedica Schweiz AG	40	2027-01-01	2026-10-30
Expiratory Muscle Training and Trunk Flexion in Parkinson's Disease Expiratory muscle strength training - Parkinson Disease	Not applicable	Not yet recruiting	General University Hospital, Prague	30	2027-01-01	2026-11-12

Showing 20 of 4774. Sign in to see all of them.

Narrower conditions

Parkinson Disease (4498)  ·  Lewy Body Disease (237)  ·  Alzheimer Disease (210)  ·  Multiple System Atrophy (204)  ·  Parkinsonian Disorders (168)  ·  Movement Disorders (164)  ·  Cognitive Dysfunction (163)  ·  Motor Activity (162)  ·  Dementia (143)  ·  Neurodegenerative Diseases (130)  ·  Dyskinesias (107)  ·  Multiple Sclerosis (98)  ·  Depression (97)  ·  Essential Tremor (96)  ·  Stroke (88)

Broader conditions

Basal Ganglia Diseases (4737)  ·  Central Nervous System Diseases (4724)  ·  Brain Diseases (4721)  ·  Nervous System Diseases (4699)  ·  Neurodegenerative Diseases (4644)  ·  Movement Disorders (4605)  ·  Parkinsonian Disorders (4500)  ·  Pathological Conditions, Signs and Symptoms (886)  ·  Signs and Symptoms (743)  ·  Mental Disorders (706)  ·  Neurologic Manifestations (606)  ·  Neurocognitive Disorders (489)  ·  Behavior (322)  ·  Tauopathies (261)

Interventions

Levodopa (89)  ·  Deep Brain Stimulation (82)  ·  Exercise (79)  ·  carbidopa, levodopa drug combination (74)  ·  Transcranial Direct Current Stimulation (51)  ·  rasagiline (46)  ·  Transcranial Magnetic Stimulation (45)  ·  Pramipexole (44)  ·  opicapone (43)  ·  rotigotine (43)  ·  Carbidopa (35)  ·  Physical Therapy Modalities (34)  ·  Control Groups (29)  ·  Apomorphine (26)  ·  entacapone (23)

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS) (63)  ·  Bial - Portela C S.A. (56)  ·  Boehringer Ingelheim (42)  ·  University of Florida (42)  ·  VA Office of Research and Development (42)  ·  University Hospital, Toulouse (39)  ·  Oregon Health and Science University (36)  ·  Radboud University Medical Center (35)  ·  University of Minnesota (34)  ·  University of Colorado, Denver (33)  ·  Washington University School of Medicine (32)  ·  AbbVie (30)  ·  National Taiwan University Hospital (27)  ·  University Hospital, Grenoble (27)  ·  Assistance Publique - Hôpitaux de Paris (25)

Countries

United States (1735)  ·  France (464)  ·  Italy (363)  ·  China (296)  ·  Germany (268)  ·  United Kingdom (263)  ·  Canada (260)  ·  Spain (229)  ·  Turkey (Türkiye) (171)  ·  Israel (125)  ·  Netherlands (121)  ·  Taiwan (119)  ·  Brazil (104)  ·  Japan (90)  ·  Austria (88)

Top investigators

Giuseppe Frazzitta, MD (16)  ·  Italo Biaggioni, MD (13)  ·  Danna Jennings, MD (11)  ·  Alice Nieuwboer, PhD (8)  ·  Bastiaan R Bloem, MD, PhD (7)

Results publications

PMID 36602886, PMID 38588457, PMID 40680102, PMID 31356217, PMID 25623333, PMID 30741694, PMID 31127735, PMID 10816186, PMID 19025984, PMID 19126811, PMID 27538531, PMID 28494751, PMID 34816053, PMID 41626017, PMID 11253156, PMID 12112073, PMID 12360555, PMID 12498954, PMID 1454205, PMID 15097290, PMID 16267188, PMID 16401616, PMID 16436781, PMID 17941858, PMID 19058133, PMID 20457959, PMID 20519680, PMID 20574039, PMID 20582993, PMID 20841416, PMID 20937936, PMID 20946640, PMID 21484867, PMID 21542016, PMID 22209649, PMID 22750016, PMID 22850494, PMID 23263599, PMID 23667214, PMID 23860343, PMID 24078735, PMID 24251381, PMID 24332532, PMID 24412048, PMID 24711047, PMID 25185211, PMID 26347184, PMID 26523919, PMID 26833853, PMID 26882318

NIH funding

2019 (15), 2023 (15), 2016 (13), 2025 (13), 2009 (11), 2018 (11), 2008 (10), 2014 (10), 2017 (10), 2004 (7), 2015 (7), 2005 (3), R01HL144568 (3), U01NS043128 (3), I01RX003397 (2)